Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

被引：24

作者：

Cortellini, Alessio ^{[1
,2
]}

Cannita, Katia ^{[3
]}

Tiseo, Marcello ^{[4
,5
]}

Cortinovis, Diego L. ^{[6
]}

Aerts, Joachim G. J., V ^{[7
]}

Baldessari, Cinzia ^{[8
]}

Giusti, Raffaele ^{[9
]}

Ferrara, Miriam G. ^{[10
,11
]}

D'Argento, Ettore ^{[10
]}

Grossi, Francesco ^{[12
]}

Guida, Annalisa ^{[13
]}

Berardi, Rossana ^{[14
]}

Morabito, Alessandro ^{[15
]}

Genova, Carlo ^{[16
]}

Antonuzzo, Lorenzo ^{[17
]}

Mazzoni, Francesca ^{[17
]}

De Toma, Alessandro ^{[18
]}

Signorelli, Diego ^{[18
,19
]}

Gelibter, Alain ^{[20
]}

Targato, Giada ^{[21
]}

Rastelli, Francesca ^{[22
]}

Chiari, Rita ^{[23
]}

Rocco, Danilo ^{[24
]}

Gori, Stefania ^{[25
]}

De Tursi, Michele ^{[26
]}

Mansueto, Giovanni ^{[27
]}

Zoratto, Federica ^{[28
]}

Filetti, Marco ^{[9
]}

Bracarda, Sergio ^{[29
]}

Citarella, Fabrizio ^{[30
]}

Russano, Marco ^{[30
]}

Cantini, Luca ^{[7
,14
]}

Nigro, Olga ^{[31
]}

Buti, Sebastiano ^{[5
]}

Minuti, Gabriele ^{[32
]}

Landi, Lorenza ^{[32
]}

Ricciardi, Serena ^{[33
]}

Migliorino, Maria R. ^{[33
]}

Natalizio, Salvatore ^{[34
]}

Simona, Carnio ^{[35
]}

De Filippis, Marco ^{[35
]}

Metro, Giulio ^{[36
]}

Adamo, Vincenzo ^{[37
]}

Russo, Alessandro ^{[37
]}

Spinelli, Gian P. ^{[38
]}

Di Maio, Massimo ^{[39
,40
]}

Banna, Giuseppe L. ^{[41
]}

Friedlaender, Alex ^{[42
]}

Addeo, Alfredo ^{[42
]}

Pinato, David J. ^{[2
,43
]}

机构：

[1] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England

[3] St Salvatore Hosp, Med Oncol, Laquila, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Osped San Gerardo, Med Oncol, Monza, Italy

[7] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands

[8] AOU Policlin Modena, Dipartimeto Oncol Ematol, Modena, Italy

[9] St Andrea Hosp, Med Oncolgy, Rome, Italy

[10] Fdn Policlin Univ Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Romae, Lazio, Italy

[12] Fdn IRCCS CaGranda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[13] Azienda Osped Santa Maria, Dept Oncol, Terni, Italy

[14] Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy

[15] Ist Nazl Tumori, IRCCS, Thorac Med Oncol, Fdn G Pascale, Naples, Italy

[16] Osped Policlin San Martino, Lung Canc Unit, IRCCS, Genoa, Italy

[17] Careggi Univ Hosp, Dept Oncol, Florence, Italy

[18] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy

[19] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[20] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[21] Univ Hosp Santa Maria Misericordia, Dept Oncol, Udine, Italy

[22] Med Oncol, Fermo Area Vasta 4, Fermo, Italy

[23] Osped Riuniti Padova Sud Madre Teresa Calcutta, Med Oncol, Monselice, Italy

[24] Monaldi Hosp, Pneumo Oncol Unit, Naples, Italy

[25] Osped Sacro Cuore Don Calabria, IRCCS, Oncol Unit, Negrar, VR, Italy

[26] Oral & Biotechnol Sci Univ G DAnnunzio, Dept Med, Chieti, Italy

[27] Spaziani Hosp, Med Oncol, Frosinone, Italy

[28] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[29] Azienda Osped Santa Maria Terni, Struttura Complessa Oncol Med & Traslaz, Terni, Italy

[30] Campus Biomed Univ, Med Oncol, Rome, Italy

[31] ASST Sette Laghi, Med Oncol, Varese, Italy

[32] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[33] St Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[34] Univ Modena & Raggio Emilia, Dipartimento Oncol Ematol, Modena, Italy

[35] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, TO, Italy

[36] Azienda Osped Perugia, Dept Med Oncol, Santa Maria Misericordia Hosp, Perugia, Italy

[37] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[38] Univ Rome Sapienza, UOC Terr Oncol Aprilia, AUSL Latina, Aprilia, Italy

[39] Univ Turin, Dept Oncol, Turin, Italy

[40] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[41] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[42] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[43] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 148卷

关键词：

Non-small cell lung cancer; Immunotherapy; PD-L1; Pembrolizumab; Performance status; Post-progression; Radiotherapy; Radiation therapy; CELL LUNG-CANCER; IMMUNE-CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; IMMUNOTHERAPY; RADIOTHERAPY; ASSOCIATION; ASSAYS;

D O I：

10.1016/j.ejca.2021.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression >50%. Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab monotherapy. Results: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95% CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). Conclusions: In the real-world scenario NSCLC patients with PD-L1 expression >50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页码：24 / 35

页数：12

共 33 条

[1] Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis [J].

Addeo, Alfredo ;

Banna, Giuseppe Luigi ;

Metro, Giulio ;

Di Maio, Massimo .

FRONTIERS IN ONCOLOGY, 2019, 9

[2] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[3] Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study [J].

Bersanelli, Melissa ;

Buti, Sebastiano ;

Giannarelli, Diana ;

Leonetti, Alessandro ;

Cortellini, Alessio ;

Lo Russo, Giuseppe ;

Signorelli, Diego ;

Toschi, Luca ;

Milella, Michele ;

Pilotto, Sara ;

Bria, Emilio ;

Proto, Claudia ;

Marinello, Arianna ;

Randon, Giovanni ;

Rossi, Sabrina ;

Vita, Emanuele ;

Sartori, Giulia ;

D'Argento, Ettore ;

Qako, Eva ;

Giaiacopi, Elisa ;

Ghilardi, Laura ;

Bettini, Anna Cecilia ;

Rapacchi, Elena ;

Mazzoni, Francesca ;

Lavacchi, Daniele ;

Scotti, Vieri ;

Ciccone, Lucia Pia ;

De Tursi, Michele ;

Di Marino, Pietro ;

Santini, Daniele ;

Russano, Marco ;

Bordi, Paola ;

Di Maio, Massimo ;

Audisio, Marco ;

Filetti, Marco ;

Giusti, Raffaele ;

Berardi, Rossana ;

Fiordoliva, Ilaria ;

Cerea, Giulio ;

Pizzutilo, Elio Gregory ;

Bearz, Alessandra ;

De Carlo, Elisa ;

Cecere, Fabiana ;

Renna, Davide ;

Camisa, Roberta ;

Caruso, Giuseppe ;

Ficorella, Corrado ;

Banna, Giuseppe Luigi ;

Cortinovis, Diego ;

Brighenti, Matteo .

LUNG CANCER, 2020, 150 :123-131

[4] Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study [J].

Bersanelli, Melissa ;

Lattanzi, Elisabetta ;

D'Abbiero, Nunziata ;

Buti, Sebastiano ;

Leonetti, Alessandro ;

Cane, Maria Giulia ;

Trapani, Salvatore ;

Gravina, Giovanni Luca ;

Porzio, Giampiero ;

Cannita, Katia ;

Di Marino, Pietro ;

Grassadonia, Antonino ;

Tinari, Nicola ;

De Tursi, Michele ;

Giaiacopi, Elisa ;

Michiara, Maria ;

Bordi, Paola ;

Perrone, Fabiana ;

Caravatta, Luciana ;

Trignani, Marianna ;

Genovesi, Domenico ;

Natoli, Clara ;

Ficorella, Corrado ;

Tiseo, Marcello ;

Cortellini, Alessio .

BIOMEDICAL REPORTS, 2020, 12 (02) :59-67

[5] KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% [J].

Brahmer, J. R. ;

Rodriguez-Abreu, D. ;

Robinson, A. G. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Leal, T. A. ;

Riess, J. W. ;

Jensen, E. ;

Zhao, B. ;

Pietanza, M. C. ;

Reck, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S1181-S1182

[6] Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer [J].

Buttner, Reinhard ;

Gosney, John R. ;

Skov, Birgit Guldhammer ;

Adam, Julien ;

Motoi, Noriko ;

Bloom, Kenneth J. ;

Dietel, Manfred ;

Longshore, John W. ;

Lopez-Rios, Fernando ;

Penault-Llorca, Frederique ;

Viale, Giuseppe ;

Wotherspoon, Andrew C. ;

Kerr, Keith M. ;

Tsao, Ming-Sound .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) :3867-+

[7] Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) [J].

Campbell, A. M. ;

Cai, W. L. ;

Burkhardt, D. ;

Gettinger, S. N. ;

Goldberg, S. B. ;

Amodio, M. ;

Kaech, S. ;

Krishnaswamy, S. ;

Decker, R. H. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01) :S36-S37

[8] Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study [J].

Cortellini, Alessio ;

De Giglio, Andrea ;

Cannita, Katia ;

Cortinovis, Diego L. ;

Cornelissen, Robin ;

Baldesarri, Cinzia ;

Giusti, Raffaele ;

D'Argento, Ettore ;

Grossi, Francesco ;

Santoni, Matteo ;

Catino, Annamaria ;

Berardi, Rossana ;

Sforza, Vincenzo ;

Rossi, Giovanni ;

Antonuzzo, Lorenzo ;

Di Noia, Vincenzo ;

Signorelli, Diego ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Follador, Alessandro ;

Rastelli, Francesca ;

Chiari, Rita ;

Gravara, Luigi Della ;

Inno, Alessandro ;

De Tursi, Michele ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Montrone, Michele ;

Citarella, Fabrizio ;

Pensieri, Maria Vittoria ;

Russano, Marco ;

Cantini, Luca ;

Nigro, Olga ;

Leonetti, Alessandro ;

Bordi, Paola ;

Minuti, Gabriele ;

Landi, Lorenza ;

De Toma, Alessandro ;

Donisi, Clelia ;

Ricciardi, Serena ;

Migliorino, Maria Rita ;

Napoli, Valerio Maria ;

Leone, Gianmarco ;

Metro, Giulio ;

Banna, Giuseppe L. ;

Friedlaender, Alex ;

Addeo, Alfredo ;

Ficorella, Corrado .

THORACIC CANCER, 2021, 12 (06) :880-889

[9] A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients [J].

Cortellini, Alessio ;

Ficorella, Corrado ;

Crisci, Roberto ;

Divisi, Duilio .

JOURNAL OF THORACIC DISEASE, 2020, 12 (10) :6107-6111

[10] Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes [J].

Cortellini, Alessio ;

Friedlaender, Alex ;

Banna, Giuseppe L. ;

Porzio, Giampiero ;

Bersanelli, Melissa ;

Cappuzzo, Federico ;

Aerts, Joachim G. J., V ;

Giusti, Raffaele ;

Bria, Emilio ;

Cortinovis, Diego ;

Grossi, Francesco ;

Migliorino, Maria R. ;

Galetta, Domenico ;

Passiglia, Francesco ;

Berardi, Rossana ;

Mazzoni, Francesca ;

Di Noia, Vincenzo ;

Signorelli, Diego ;

Tuzi, Alessandro ;

Gelibter, Alain ;

Marchetti, Paolo ;

Macerelli, Marianna ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Inno, Alessandro ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Santoni, Matteo ;

Tudini, Marianna ;

Ghidini, Michele ;

Filetti, Marco ;

Catino, Annamaria ;

Pizzutilo, Pamela ;

Sala, Luca ;

Occhipinti, Mario Alberto ;

Citarella, Fabrizio ;

Marco, Russano ;

Torniai, Mariangela ;

Cantini, Luca ;

Follador, Alessandro ;

Sforza, Vincenzo ;

Nigro, Olga ;

Ferrara, Miriam G. ;

D'Argento, Ettore ;

Leonetti, Alessandro ;

Pettoruti, Linda ;

Antonuzzo, Lorenzo ;

Scodes, Simona .

CLINICAL LUNG CANCER, 2020, 21 (06) :498-+

← 1 2 3 4 →

Post-progression outcomes of NSCLC patients with PD-L1 expression &gt; 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study